Senores Pharmaceuticals Ltd. reports revenue of ₹288 Cr in 9MFY25, with a 157% Y-o-Y growth
Formfees
24/01/2025
Ahmedabad: Senores Pharmaceuticals Ltd. has reported revenue of ₹288 Cr during 9MFY25 ending 31st December,2024, reflecting a robust growth of 157%. The exceptional financial performance underscores the company’s strong business strategies and operational excellence.
Key Highlights
- Total Revenue is 288 Cr which is 157% increase
- PAT after MI is 41 Cr which is 162% increase
- EBITDA is 74 Cr which is 287% increase
- Regulated market business revenues stood at 180.5 Cr, a growth of ~100% on a Y-o-Y basis
- Emerging markets business revenues stood at 84.6 Cr, growing by more than 10 times on a Y-o-Y basis
Commenting on the results, Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said, “We are pleased to report strong performance for Q3 and 9MFY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our revenue and profitability for 9MFY25 have increased by over 150% year-on-year, and we are optimistic about sustaining this momentum going forward.
In Regulated Markets, robust growth in the CDMO/CMO segment was partly offset by a softer performance in the Marketed Products segment, which was impacted by the high base of Q3FY24. The consolidation of acquired businesses has resulted in strong growth in the Emerging Markets segment for Q3FY25. Year-on-year, the Regulated Markets and Emerging Markets businesses grew by approximately 100% and over 10 times, respectively, for 9MFY25.
In 9MFY25, we launched one new product and received ANDA approval for five products in the Regulated Markets business, bringing our total ANDA approvals to 24.
Our Emerging Markets business is growing well through portfolio and footprint expansion. Our registered product portfolio in the Emerging Markets business expanded to 267 products. With a strong product portfolio, we are now realigning our go-to-market models to make our Emerging Markets operations more profitable.
We are seeing significant traction and scale-up in our CDMO/CMO segment. Currently, we manufacture 21 products in this business and expect faster growth with the addition of new products, customers, and increased wallet share from existing customers.
We remain focused on executing our business strategies across segments and are confident that healthy growth will continue in the year ahead.”
